Cantor Fitzgerald Initiates Coverage On Arcturus Therapeutics with Overweight Rating, Announces Price Target of $71
Cantor Fitzgerald analyst Brian Cheng initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight rating and announces Price Target of $71.
10 Biggest Price Target Changes For Monday
SVB Leerink raised Natera, Inc. (NASDAQ: NTRA) price target from $140 to $160. Natera shares fell 0.4% to close at $102.88 on Friday.
Barclays Downgrades Arcturus Therapeutics to Underweight, Lowers Price Target to $25
Barclays analyst Gena Wang downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Equal-Weight to Underweight and lowers the price target from $33 to $25.
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 13)
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 10)
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell
• Revlon (NYSE:REV) is likely to report earnings for its first quarter.
• Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.